Presentation is loading. Please wait.

Presentation is loading. Please wait.

Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer  Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui,

Published byAndrew Bruce Modified over 5 years ago

Similar presentations

Presentation on theme: "Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer  Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui,"— Presentation transcript:

1 Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer 
Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui, MD, Shinichi Toyooka, MD, Susumu Kanazawa, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 142, Issue 1, Pages (July 2011) DOI: /j.jtcvs Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 RFA for a 79-year-old woman with clinical stage IA NSCLC. A, CT image before the procedure shows a tumor (arrow) of 29 mm in maximum diameter in the left upper lobe. B, PET/CT image before the procedure shows marked accumulation of 18F-fluorodeoxy glucose into the tumor (arrow). C, CT-fluoroscopic image during the procedure shows that a multitined expandable electrode (arrows) is introduced into the tumor. D, PET/CT image 3 months after the procedure shows no obvious accumulation of 18F-fluorodeoxy glucose into the tumor (arrow). E, CT image 31 months after the procedure shows considerable tumor involution (arrow). The Journal of Thoracic and Cardiovascular Surgery  , 24-30DOI: ( /j.jtcvs ) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Summary of survival outcomes of 50 patients with clinical stage I NSCLC treated with RFA. RFA, Radiofrequency ablation. The Journal of Thoracic and Cardiovascular Surgery  , 24-30DOI: ( /j.jtcvs ) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Overall survivals are 94% at 1 year, 86% at 2 years, 74% at 3 years, 67% at 4 years, and 61% at 5 years. The cancer-specific survivals are 100% at 1 year, 93% at 2 years, 80% at 3 years, 80% at 4 years, and 74% at 5 years. The disease-free survivals are 82% at 1 year, 64% at 2 years, 53% at 3 years, 46% at 4 years, and 46% at 5 years. RFA, Radiofrequency ablation. The Journal of Thoracic and Cardiovascular Surgery  , 24-30DOI: ( /j.jtcvs ) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 Survivals of stage IA and IB cancers are 95% and 92% at 1 year, 89% and 75% at 2 years, 83% and 50% at 3 years, 73% and 50% at 4 years, and 66% and 50% at 5 years, respectively. Survivals are not significantly different between the 2 groups (P = .057). RFA, Radiofrequency ablation. The Journal of Thoracic and Cardiovascular Surgery  , 24-30DOI: ( /j.jtcvs ) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer  Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui,"

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Stephen R. Broderick, MD, MPHS 

Stephen R. Broderick, MD, MPHS 
Timothy L. Van Natta, MD, Mark D. Iannettoni, MD, MBA 

Timothy L. Van Natta, MD, Mark D. Iannettoni, MD, MBA 
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Lung cancer screening: No more excuses

Lung cancer screening: No more excuses
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery  Yoshifumi Sano, MD, Susumu Kanazawa,

A Novel Strategy for Treatment of Metastatic Pulmonary Tumors: Radiofrequency Ablation in Conjunction with Surgery  Yoshifumi Sano, MD, Susumu Kanazawa,
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer  Masatsugu Hamaji, MD, Mark S. Allen,
Sleeve lung resection for lung cancer: Analysis according to the type of procedure  Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure  Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,
John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N
Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD,

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer  Walter Weder, MD, Stéphane Collaud, MD,

Similar presentations

Ads by Google